BioNTech SE (NASDAQ: BNTX) is a German biotechnology company headquartered in Mainz, Germany, founded in 2008 by Ugur Sahin and Ozlem Tureci. While primarily known for its revolutionary mRNA technology and COVID-19 vaccine (Comirnaty/BNT162b2), BioNTech has built a diversified pipeline spanning oncology, infectious diseases, and internal medicine[1].
| Year | Milestone |
|---|---|
| 2008 | Founded by Ugur Sahin and Ozlem Tureci in Mainz, Germany |
| 2018 | Partnership with Pfizer for mRNA vaccines |
| 2020 | First COVID-19 vaccine authorized for emergency use (Pfizer-BioNTech) |
| 2021 | Expanded focus on oncology and neurodegenerative diseases |
| 2022+ | Multiple oncology programs in clinical development |
BioNTech has developed multiple technology platforms for developing novel therapeutics:
| Platform | Description |
|---|---|
| Cell therapies | CAR-T and other cell therapy approaches |
| Targeted antibodies | Monoclonal and bispecific antibodies |
| Small molecule immunomodulators | Novel immunomodulatory compounds |
| Ribologicals | Novel RNA-based therapeutics |
| Next-generation immunomodulators | Next-gen checkpoint modifiers |
As of 2025-2026, BioNTech's pipeline includes:
BioNTech has one of the most comprehensive oncology pipelines in biotech:
| Category | Number of Programs |
|---|---|
| Phase 2 and Phase 3 trials | 25+ |
| Novel-novel combination trials | 10+ |
| Clinical-stage candidates | Multiple |
Key oncology programs include:
| Program | Indication | Development Phase |
|---|---|---|
| COMIRNATY | COVID-19 | Authorized/Approved |
| Next-generation COVID vaccines | COVID-19 | Development |
| Flu vaccine | Influenza | Development |
| Other respiratory vaccines | Multiple | Development |
Based on publicly available information, BioNTech's primary focus is on oncology and infectious diseases. The company has not disclosed significant clinical-stage programs for neurological diseases such as Alzheimer's or Parkinson's disease. Research in this area, if any, appears to be early-stage or not publicly disclosed.
The company's mRNA platform theoretically could be applied to neurological diseases through protein replacement therapies, but no clinical programs have been announced.
BioNTech maintains strategic partnerships with leading pharmaceutical companies:
| Partner | Focus Area |
|---|---|
| Pfizer | mRNA vaccines (COVID-19, flu, others) |
| Genentech | Oncology collaboration |
| University of Mainz | Academic research partnerships |
| Other collaborations | Various |
| Item | Detail |
|---|---|
| Headquarters | Mainz, Germany |
| Founded | 2008 |
| Founders | Ugur Sahin, Ozlem Tureci |
| Stock exchange | NASDAQ |
| Ticker symbol | BNTX |
| Employees | 4,000+ |